Q2 FY27 revenue rises 18.9%, but margin slips and H1 loss widens

Management guided margin improvementOrder pipeline disclosedInvestor Communications View source PDF Explain this filing

ZIMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹136.00

prior close

₹137.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+0.8

15m

+1.0

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+0.0pendingpending

Next day

-3.6pendingpending

———

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zim Laboratories reported Q2 and H1 FY27 results. Q2 operating revenue rose 18.9% to Rs 105.4 crore, but profit before interest, tax, depreciation and amortisation fell 1.2% to Rs 7.7 crore and margin eased to 7.3%. H1 revenue rose 24.4% to Rs 199.6 crore, while net loss widened to Rs 6.1 crore. Australia granted good manufacturing practice certification, EU recertification is pending, and a developed-market order was secured.

Likely market impact

Revenue growth and market access help, but weaker margins, a larger H1 loss and higher borrowings may weigh on near-term stock sentiment.